Member Profile

Dr. Carmen Escuriola- Ettingshausen
MD
Key Publications
  1. A review of immune tolerance induction with Haemate P in haemophilia A, Escuriola Ettingshausen C.; Kreuz,W. Haemophilia 2014. Vol. 20: 333-339.
  2. Inhibitors in patients with haemophilia A. Kreuz, W.; Ettingshausen, C.E. Thromb. Research 2014. In press.
  3. Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study. Kenet,G.; Bidlingmaier,C.; Bogdanova,N.; Ettingshausen,C.E.; Goldenberg,N.; Gutsche,S.; Halimeh,S.; Holzhauer,S.; Kurnik,K.; Limperger,V.; Junker,R.; Nowak-Gottl,U. Thromb. Res. 2014. Vol. 133: 544-549.
  4. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? Ettingshausen,C.E.; Kreuz,W. Haemophilia. 2013 Vol.19: 12-17.
  5. Factor VIII products and inhibitor development in severe hemophilia A, Gouw,S.C.; van der Bom,J.G.; Ljung,R.; Escuriola,C.; Cid,A.R.; Claeyssens-Donadel,S.; van,Geet C.; Kenet,G.; Makipernaa,A.; Molinari,A.C.; Muntean,W.; Kobelt,R.; Rivard,G.; Santagostino,E.; Thomas,A.; van den Berg,H.M., N.Engl. J. Med. 2013 Vol.368: 231-239.

Current Positions/Chairs:

  • Co-director
    Haemophilia Centre Rhein Main - HZRM
  • Member
    German, Swiss and Austrian Society For Thrombosis and Haemostasis Research (GTH) and the International Society for Thrombosis and Haemostasis (ISTH)

Key Institutions

  • Haemophilia Centre Rhein Main - HZRM
    Frankfurt-Mörfelden, Germany

Research Interests

  • Haemorrhagic disorders, particularly in treatment of haemophiliacs and haemophiliacs with inhibitors

Publications

December 3, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)

Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535